Art­bio emerges with $23M to make ra­di­oli­gand ther­a­pies for prostate can­cer, with field still in 'ear­ly days'

An­oth­er start­up is en­ter­ing the ra­dio­phar­ma mar­ket, backed by F-Prime Cap­i­tal and Omega Funds, with an ex­pe­ri­enced team from No­var­tis and Bay­er.

Art­bio is launch­ing with $23 mil­lion and a pipeline of al­pha ra­di­oli­gand ther­a­pies, in­clud­ing a PS­MA-di­rect­ed prostate can­cer pro­gram. It’s an area of on­col­o­gy tar­get­ed by oth­ers in the field, in­clud­ing No­var­tis’ Plu­vic­to — which ran in­to sup­ply is­sues this win­ter — as well as the re­cent­ly de­buted Con­ver­gent Ther­a­peu­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER